Joel Schlessinger, MD, FAAD
Joel Schlessinger, MD is a practicing, double board-certified dermatologist, Mohs surgeon as well as cosmetic surgeon, in Omaha, Nebraska. Dr. Schlessinger has more than 30 years of experience treating a wide variety of skin conditions, including skin cancers, and performing aesthetic treatments, such as neurotoxins & fillers for facial wrinkles & volume loss, total facial rejuvenation with lasers such as MOXI and HALO Laser Resurfacing and body contouring with SmartLipo and CoolSculpting ELITE.
Dr. Schlessinger is the CEO of LovelySkin.com, the largest dermatologist-owned and operated skin care website in the world and is also the emeritus editor, Cosmetic Surgery, for Practical Dermatology. Dr. Schlessinger is the former president of the American Society of Cosmetic Dermatology and Aesthetic Surgery and is the past president of the Nebraska Dermatology Society.
As a board-certified Dermatologist and Cosmetic Surgeon (and formerly board-certified as a pediatrician), Dr. Schlessinger is the winner of the Best Dermatologist and Best Cosmetic Surgeon in Omaha since 2000. Dr. Schlessinger is a member of the NewBeauty BrainTrust and has also been distinguished as a New Beauty Top Doctor & Verified Expert Injector since 2019.
Financial relationships
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:AllerganTopic:AestheticsDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:Alphaeon CorporationTopic:AestheticsDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:GaldermaTopic:AestheticsDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:RevanceTopic:AestheticsDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:NexTechTopic:Product developmentDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:AbbvieTopic:Clinical researchDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:Aclaris TherapeuticsTopic:Clinical researchDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:AllerganTopic:Clinical researchDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:Boehringer IngelheimTopic:Clinical researchDate added:05/08/2026Date updated:05/08/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:ChemoCentryxTopic:Clinical researchDate added:05/08/2026Date updated:05/08/2026

Facebook
X
LinkedIn
Forward